Results 21 to 30 of about 212,106 (307)

Minimal Residual Disease [PDF]

Leukemia Supplements, 2003
The aim of minimal residual disease (MRD) studies in patients with acute leukemia is to measure initial treatment response accurately, provide an assessment of the residual leukemic burden throughout therapy and detect relapse early. Therefore, information resulting from MRD monitoring can substantially improve many facets of clinical management ...
openaire   +2 more sources

A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia

Haematologica, 2019
Minimal (or ‘measurable’) residual disease in acute lymphoblastic leukemia appears to be a prognostic indicator, with potential value in informing individualized treatment decisions.
Renato Bassan, Monika Brüggemann, Hoi-Shen Radcliffe, Elizabeth Hartfield, Georg Kreuzbauer, Sally Wetten   +5 more
doaj   +1 more source

Metabolic memory underlying minimal residual disease in breast cancer

Molecular Systems Biology, 2021
Tumor relapse from treatment‐resistant cells (minimal residual disease, MRD) underlies most breast cancer‐related deaths. Yet, the molecular characteristics defining their malignancy have largely remained elusive.
Ksenija Radic Shechter, Eleni Kafkia, Katharina Zirngibl, Sylwia Gawrzak, Ashna Alladin, Daniel Machado, Christian Lüchtenborg, Daniel C Sévin, Britta Brügger, Kiran R Patil, Martin Jechlinger   +10 more
doaj   +1 more source

Flowcytometric and DNA Analysis Minimal Residual Disease (MRD) in Childhood B-Lineage lymphoblastic leukemia [PDF]

International Journal of Hematology-Oncology and Stem Cell Research, 2005
Background: Induction Chemotherapy for Acute Lymphoblastic Leukemia achieves complete remis¬sion in over 90% of children. It is apparent therefore that many patients in clinical remission and with¬out residual disease detectable by conventional light ...
P Vossough, M Faranoush, Z Emami, Gh Bahoush, Kh Arjmandi, Sh Ansari, M Alebouyeh, E Shahgholi, A.A Hedayatiasl   +8 more
doaj   +1 more source

Sickle Cell Disease Is an Inherent Risk for Asthma in a Sibling Comparison Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Sickle cell disease (SCD) and asthma share a complex relationship. Although estimates vary, asthma prevalence in children with SCD is believed to be comparable to or higher than the general population. Determining whether SCD confers an increased risk for asthma remains challenging due to overlapping symptoms and the ...
Suhei C. Zuleta De Bernardis, Okeleji Olayinka, Mariam Z. Quraishi, Lakshmi V. Srivaths, Deborah L. Brown, Neethu M. Menon, Ricardo A. Mosquera, Ashwin P. Patel, James M. Stark, Aravind Yadav   +9 more
wiley   +1 more source

Pazopanib Combined With Vincristine and Irinotecan in Relapsed Wilms Tumor: Encouraging Outcomes in a Heavily Pretreated Pediatric Cohort

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background While Wilms tumor (WT) typically has a favorable prognosis, relapsed cases—especially those with high‐risk histology—remain therapeutically challenging after intensive frontline therapy. The combination of vincristine and irinotecan has demonstrated activity in pediatric solid tumors, and pazopanib, a multi‐targeted tyrosine kinase ...
Maria Debora De Pasquale, Alessandro Crocoli, Giuseppe Maria Milano, Pierluigi Di Paolo, Francesca Diomedi Camassei, Ida Russo, Annalisa Serra   +6 more
wiley   +1 more source

Comparison between qualitative and real-time polymerase chain reaction to evaluate minimal residual disease in children with acute lymphoblastic leukemia

Revista Brasileira de Hematologia e Hemoterapia, 2015
Introduction: Minimal residual disease is an important independent prognostic factor that can identify poor responders among patients with acute lymphoblastic leukemia.
Francisco Danilo Ferreira Paula, Silvana Maria Elói-Santos, Sandra Guerra Xavier, Mônica Aparecida Ganazza, Patricia Yoshioka Jotta, José Andrés Yunes, Marcos Borato Viana, Juliana Godoy Assumpção   +7 more
doaj   +1 more source

Personalizing the Pediatric Hematology/Oncology Fellowship: Adapting Training for the Next Generation

Pediatric Blood &Cancer, EarlyView.
ABSTRACT The pediatric hematology‐oncology fellowship training curriculum has not substantially changed since its inception. The first year of training is clinically focused, and the second and third years are devoted to scholarship. However, this current structure leaves many fellows less competitive in the current job market, resulting in ...
Scott C. Borinstein, Melissa J. Rose, Scott Moerdler, Richard Ho   +3 more
wiley   +1 more source

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia

Revista Brasileira de Hematologia e Hemoterapia, 2015
Minimal residual disease is the most powerful predictor of outcome in acute leukemia and is useful in therapeutic stratification for acute lymphoblastic leukemia protocols. Nowadays, the most reliable methods for studying minimal residual disease in acute
Maura Rosane Valério Ikoma, Miriam Perlingeiro Beltrame, Silvia Inês Alejandra Cordoba Pires Ferreira, Elizabeth Xisto Souto, Mariester Malvezzi, Mihoko Yamamoto   +5 more
doaj   +1 more source

The MedSupport Multilevel Intervention to Enhance Support for Pediatric Medication Adherence: Development and Feasibility Testing

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction We developed MedSupport, a multilevel medication adherence intervention designed to address root barriers to medication adherence. This study sought to explore the feasibility and acceptability of the MedSupport intervention strategies to support a future full‐scale randomized controlled trial.
Elizabeth G. Bouchard, Hital Patel, Paula C. Vincent, Justine Kahn, Kira Bona, Thai Hoa Tran, Elisa M. Rodriguez, Kristopher Attwood, Kara M. Kelly   +8 more
wiley   +1 more source